Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4% - Here's What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) fell 6.4% during trading on Wednesday . The company traded as low as $19.93 and last traded at $19.74. 329,516 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 763,110 shares. The stock had previously closed at $21.09.

Wall Street Analyst Weigh In

Several analysts recently issued reports on GPCR shares. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. William Blair started coverage on Structure Therapeutics in a report on Friday. They issued an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Stock Performance

The business has a fifty day simple moving average of $26.58 and a 200-day simple moving average of $33.57. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -32.09 and a beta of -2.75.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Remove Ads

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd increased its holdings in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares during the period. GAMMA Investing LLC grew its position in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $34,000. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $40,000. Finally, Assetmark Inc. raised its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.